Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides

US5215971A · kind A · utility

Assignee

• MEDIVIR AB · SE

Inventors

• Roelf Datema · Cheshire, US
• Kristina B. Gotthammar · Boo, SE
• Karl N. G. Johansson · Fagersta, SE
• Zsuzsanna M. I. Kovacs · Albenga, IT
• Bjorn Lindborg · Björnlunda, SE
• Goran B. Stening · Gately Drive, SE
• Bo F. berg · Strängnäs, SE

Key dates

• Filing date: Jul 2, 1991
• Grant date: Jun 1, 1993
• Expiry date: Jul 2, 2011

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of a compound of the formula ##STR1## wherein A is .beta.-2'-deoxy-D-ribofuranosyl or .beta.-D-arabinofuranosyl; PA0 R.sup.1 is hydroxy or amino; PA0 R.sup.2 is cycloalkyl or alkyl-substituted cycloalkyl containing 1-5 carbon atoms; saturated or unsaturated, straight or branched alkyl containing 1-5 carbon atoms which may be unsubstituted or substituted with halogen, hydroxy, mercapto, trifluoroalkyl or difluoroalkyl containing 1-3 carbon atoms, phenoxy or alkoxy containing 1-3 carbon atoms; phenyl or phenylalkyl containing 1-3 carbon atoms in the alkyl part, or a physiologically acceptable salt thereof, for manufacture of a medicament for therapeutic or prophylactic control or treatment of retrovirus, especially HIV, or hepatitis B virus infections in animal and man and to a method of such treatment.